ADC Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target
H.C. Wainwright Maintains ADC Therapeutics(ADCT.US) With Buy Rating, Maintains Target Price $8
Positive Buy Rating Driven by Promising ADC Therapeutics Trial and Financial Projections
ADC Therapeutics Price Target Maintained With a $10.00/Share by Guggenheim
ADC Therapeutics Analyst Ratings
Promising Efficacy in LOTIS-7 Trial Boosts Buy Rating for ADC Therapeutics
H.C. Wainwright Maintains ADC Therapeutics(ADCT.US) With Buy Rating, Maintains Target Price $8
RBC Capital Maintains ADC Therapeutics(ADCT.US) With Buy Rating, Maintains Target Price $8
ADC Therapeutics Initiated at Overweight by Stephens & Co.
ADC Therapeutics Analyst Ratings
ADC Therapeutics (ADCT) Receives a Buy From RBC Capital
Stephens Initiates ADC Therapeutics(ADCT.US) With Buy Rating, Announces Target Price $6
ADC Therapeutics Price Target Maintained With a $8.00/Share by RBC Capital
ADC Therapeutics Analyst Ratings
RBC Capital Reaffirms Their Buy Rating on ADC Therapeutics (ADCT)
Capital One Financial Maintains ADC Therapeutics(ADCT.US) With Buy Rating, Cuts Target Price to $9
Buy Rating Upheld for ADC Therapeutics SA Amidst Strong Financials and Promising Oncology Pipeline
ADC Therapeutics Analyst Ratings
Buy Rating Affirmed for ADC Therapeutics on Strong Zynlonta Clinical Data and Strategic Growth Outlook